-
From Evidence to Excel: Generative AI for Automated SLR Data Extractions
Sep 9, 2025, 16:22 PM -
Evaluating the Costs and Benefits of Innovative Pricing and Payment Models in Europe
Sep 9, 2025, 16:22 PM -
Negative Symptoms in Schizophrenia: An Observational Study of Patient Characteristics Cost and Healthcare Resource Utilization From a US Healthcare Database
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Pegcetacoplan for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in Patients With Treatment Failure After C5 Inhibitor Therapy: An Analysis From the Brazilian Public Healthcare System Perspective
Sep 9, 2025, 16:22 PM -
Primary Lateral Sclerosis (PLS): A Targeted Literature Review of Symptoms, Progression, and Outcomes to Inform Evidence Gaps for Rare Neurological Disorders
Sep 9, 2025, 16:22 PM -
An Algorithm to Identify Immunocompromised Patients in French Claims Data for Rapid Preventive or Therapeutic Interventions
Sep 9, 2025, 16:22 PM -
Utilizing the Patient-Specific Needs Evaluation for Data-Supported and Individualized Treatment (UNITE)
Sep 9, 2025, 16:22 PM -
Subsequent Treatments and NICE Appraisals for DLBCL: A Review of Committee Discussions
Sep 9, 2025, 16:22 PM -
Rare Disease Awareness Among Physicians in Five European Countries: Results of a Cross-Sectional Survey
Sep 9, 2025, 16:22 PM -
Is Europe and European Evidence Development an Afterthought in Pharmaceutical Early Stage Development Decisions? An Exploratory Qualitative Survey
Sep 9, 2025, 16:22 PM -
Association of eGFR Decline and Cardiovascular Outcomes in Chronic Kidney Disease Patients: Feasibility of Frequency Matching Replicating Event-Driven Clinical Trials With Real-World Data Long-Term
Sep 9, 2025, 16:22 PM -
Development of a Content-Valid Patient-Reported Outcome (PRO) Measure for Adults With Glycogen Storage Disease Type 1a (GSD1a): The GSD1a Symptom Diary-Adult Version
Sep 9, 2025, 16:22 PM -
An Analysis of Differences in Patient Access to CGRP Migraine Treatments in the Nordic Region
Sep 9, 2025, 16:22 PM -
Applying G-methods to Account for Treatment Switching in Postmarketing Effectiveness Evaluation: A Case Study of GLP-1 Receptor Agonists for Diabetic Kidney Disease
Sep 9, 2025, 16:22 PM -
Measuring Quality of Life in Huntington’s Disease Using a Proxy Approach: Validation of the HD-mQoL-prx Measure
Sep 9, 2025, 16:22 PM -
Applying the Evidence-Generation Continuum Concept to Support Patient Access to Innovative Therapies in France: A Use Case in Rare Diseases
Sep 9, 2025, 16:22 PM -
Routing Decisions and Outcomes of NICE Technology Appraisals Underproportionate Approach to Technology Appraisals
Sep 9, 2025, 16:22 PM -
Cost-Savings Assessment of Fitusiran Prophylaxis in Minimizing Breakthrough Bleeding Treatment Expenses in the United Arab Emirates
Sep 9, 2025, 16:22 PM -
Effectiveness of Psychosocial Interventions for Adults With Substance Use Disorder and Co-Occurring Mental Health Disorder: An Umbrella Review
Sep 9, 2025, 16:22 PM -
Rescaled Tariff Regression for EQ-5D-5L Health State Valuation: An Equivalent Alternative to the Nonparametric Crosswalk
Sep 9, 2025, 16:22 PM
